Bayer's Pipeline Wins Fail to Dislodge Glyphosate Overhang as Shares Slide 10%

Bayer shares slid 10% over seven days to EUR 45.02 despite FDA Priority Review for Lynkuet and EU pesticide talks, as US glyphosate litigation weighed.

Bayer's late-stage drug portfolio notched a pair of regulatory victories this week, yet the market greeted them with a shrug. Instead, persistent legal and regulatory uncertainty tied to the company's US glyphosate exposure kept the Leverkusen-based group's stock under pressure, with the shares finishing Friday at EUR 45.02 — a seven-day decline of 10%.

The absence of a single fresh catalyst behind the selling underscored how thoroughly the North American litigation narrative has come to dominate investor sentiment. According to media reports, lingering courtroom and regulatory risks in the United States were enough on their own to sour the mood, pushing the stock sharply lower on Thursday. Even so, Bayer remains up 22% since the start of the year, having clawed back ground from earlier lows. Periods of legal uncertainty, however, have repeatedly forced a more cautious re-rating of the equity.

Missouri Trial Opens as EU Weighs Pesticide Rules

The legal front saw concrete developments. A Roundup trial got underway Tuesday in Missouri, where three plaintiffs accuse Bayer's Monsanto unit of inadequate product testing. Reuters has suggested the proceedings could set a precedent for future waves of claims. Separately, EU member states on Wednesday settled on a negotiating position that would restrict indefinite approvals for pesticides such as glyphosate to low-risk substances only.

FDA Grants Lynkuet Priority Review

Against that troubled backdrop, Bayer's research engine kept moving. The US Food and Drug Administration on Monday granted Priority Review to the drug candidate Lynkuet (elinzanetant) for an additional indication — the treatment of moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer. The designation meaningfully shortens the standard US regulatory review timeline and reinforces the company's late-stage pipeline in a core therapeutic area.

Progress extended to other research fields as well. On Wednesday, Bayer and its subsidiary BlueRock Therapeutics disclosed that both the FDA and the European Medicines Agency had awarded Orphan Drug status to the cell therapy candidate lemiretprocel (OpCT-001), currently being evaluated in a Phase 1/2a study targeting primary photoreceptor diseases.

On the consumer health side, Bayer launched the stool softener MiraSOFT, containing the active ingredient docusate sodium, at US pharmacy chain CVS Pharmacy on Tuesday. The product is stocked in more than 7,000 locations.

Leadership Shift and Financing Moves

Organizational changes accompanied the pipeline news. Dr. Christoph Koenen took on the role of Chief Medical Officer of the pharmaceuticals division in addition to his existing duties, tasked with steering the segment's medical strategy. On the financing side, Bayer secured additional headroom. These operational steps, though, largely went unnoticed on the trading floor, drowned out by caution over the legal situation.

Q3 Report Due November 3

A clearer picture of operating performance will arrive with the next earnings release. Bayer is scheduled to publish its quarterly statement for the third quarter of 2026 on November 3, 2026, at 07:30 CET, followed by an investor conference at 14:00 CET.